Sun Pharma faces potential impact from the US 100% tariff on patented drugs, which could reduce FY26–27 earnings by 8–10%. Generic drugs remain exempt. The company’s innovative portfolio, strong cash position, and mitigation options support steady revenue growth, maintaining HSBC’s Buy rating with Rs 1,850 target.